The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at Jonsson Comprehensive Cancer Center, discusses the implications from the phase III MONALEESA-3 trial for postmenopausal women with HR+ and HER2 negative advanced breast cancer
Tags: ESMO 2019
Published: 11 October 2019
Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma
Dr. Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, offers her thoughts on the real-world evidence presented at ASH 2019 ...
Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory ...
John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, elaborates on ...
Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, on whether ...
Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers how physicians should be thinking about the use of BTK inhibitors ...
John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, tells us ...
Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and ...
Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, considers ...
John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, shares outcomes ...
Follow @OBRTweets